Clinical Trials

Botanix Pharmaceuticals periodically runs clinical studies for its synthetic cannabinoid products. We will soon be recruiting people aged 18 to 65 years old who have moderate to severe papulopustular rosacea and meet other eligibility and inclusion criteria, to participate in our BTX 1702 rosacea trial in Australia and New Zealand.

The Phase 1b study will now be a randomised, double blind, vehicle-controlled study in patients with moderate to severe papulopustular rosacea, which is planned to enrol approximately 120 patients across 11 dermatology clinic sites.

To learn more about the qualifying criteria for this study and to register your interest, please complete this form.